We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-8.48%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$216M
Cap. Flow
+$438M
Cap. Flow %
31.76%
Top 10 Hldgs %
59.8%
Holding
50
New
13
Increased
11
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$105M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$65M
3
AMRN
Amarin Corp
AMRN
+$61.1M
4
SWTX
SpringWorks Therapeutics
SWTX
+$49.1M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$34.7M

Top Sells

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$1.17M

Sector Composition

Rank Sector Weight
1 Healthcare 78.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
26
Kura Oncology
KURA
$800M
$12.8M 0.93%
844,789
– –
GBT
27
DELISTED
Global Blood Therapeutics, Inc.
GBT
$12.1M 0.88%
250,000
– –
ZGNX
28
DELISTED
Zogenix, Inc.
ZGNX
$12M 0.87%
+300,000
New +$13.8M
BLU
29
DELISTED
BELLUS Health Inc.
BLU
$11.3M 0.82%
+1,775,000
New +$12.5M
AKRO
30
DELISTED
Akero Therapeutics
AKRO
$11M 0.8%
482,495
+85,800
+22% +$2M
KDMN
31
DELISTED
Kadmon Holdings, Inc.
KDMN
$10.1M 0.73%
4,000,000
+311,900
+8% +$774K
VYGR icon
32
Voyager Therapeutics
VYGR
$183M
$8.61M 0.62%
500,000
+400,000
+400% +$8.4M
TECX
33
Tectonic Therapeutic
TECX
$529M
$8.47M 0.61%
+50,000
New +$11.3M
IMMU
34
CALL
DELISTED
Immunomedics Inc
IMMU
$7.96M 0.58%
600,000
– –
LXRX icon
35
Lexicon Pharmaceuticals
LXRX
$1.03B
$7.53M 0.55%
+2,500,000
New +$7.74M
ACHN
36
DELISTED
Achillion Pharmaceuticals
ACHN
$7.2M 0.52%
+2,000,000
New +$7.71M
IDYA icon
37
IDEAYA Biosciences
IDYA
$3.42B
$6.88M 0.5%
764,252
– –
LJPC
38
DELISTED
La Jolla Pharmaceutical Company
LJPC
$6.82M 0.49%
775,000
+200,000
+35% +$1.89M
MTNB icon
39
Matinas BioPharma
MTNB
$1.88M
$6.42M 0.47%
203,766
– –
CBAY
40
DELISTED
Cymabay Therapeutics
CBAY
$6.4M 0.46%
1,250,000
– –
LITS
41
Lite Strategy Inc
LITS
$32.8M
$4.89M 0.35%
145,655
– –
SNDX icon
42
Syndax Pharmaceuticals
SNDX
$1.69B
$2.99M 0.22%
+400,000
New +$3.64M
RCUS icon
43
Arcus Biosciences
RCUS
$3.55B
$2.73M 0.2%
+300,000
New +$2.41M
MRSN
44
DELISTED
Mersana Therapeutics
MRSN
$2.66M 0.19%
67,232
-16,128
-19% -$1.17M
KNSA icon
45
Kiniksa Pharmaceuticals
KNSA
$5.8B
$2.47M 0.18%
290,577
– –
KALV
46
DELISTED
KalVista Pharmaceuticals
KALV
$2.32M 0.17%
200,000
– –
CLRB icon
47
Cellectar Biosciences
CLRB
$20.5M
$1.84M 0.13%
3,067
– –
PRTA icon
48
Prothena Corp
PRTA
$425M
$624K 0.05%
+79,598
New +$707K
ELDN icon
49
Eledon Pharmaceuticals
ELDN
$261M
$201K 0.01%
18,021
– –
ESPR
50
CALL
DELISTED
Esperion Therapeutics
ESPR
– –
-250,000
Closed -$11.6M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Boxer Capital held 50 positions worth $1.38B, up 19% from $1.16B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Boxer Capital deployed $438M of net new capital in Q3 2019, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Sarepta Therapeutics: 550,000 shares worth $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $1.17M trimmed.

  • Boxer Capital's largest Q3 2019 buy was Sarepta Therapeutics: 550,000 shares worth $41.4M.
  • Boxer Capital added most to Spark Therapeutics, Inc. Common Stock in Q3 2019, an estimated $105M increase.
  • Boxer Capital's biggest Q3 2019 reduction was Mersana Therapeutics, cutting an estimated $1.17M.
  • Boxer Capital's ten largest holdings make up 60% of its $1.38B portfolio in Q3 2019.
  • Boxer Capital opened 13 new positions and closed 1 in Q3 2019.
  • Boxer Capital's portfolio value rose 19% quarter-over-quarter to $1.38B.

Based on Boxer Capital's 13F filing for Q3 2019, filed 14 Nov 2019.